SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.

CONCLUSIONS: We were able to reduce equipotent total fractions of SBRT from 15 to 5 without exceeding protocol-defined acute/subacute toxicity limits. With limited follow-up, disease control appears comparable to standard treatment. We continue to enroll to the 42.5 Gy/5 fx cohort and follow patients for late toxicity. TRIAL REGISTRATION: ClinicalTrials.gov NCT01984502. PMID: 28253270 [PubMed - in process]
Source: Cancer Control - Category: Cancer & Oncology Authors: Tags: PLoS One Source Type: research